knowledge -WSS

knowledge

author：explore 2025-09-04 02:29:20 - browse：7

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Eisai exec who led development of Alzheimer’s drug to retire

hotspot

WSS

ACA's risk program benefits Blue Cross Blue Shield insurers

Pandemic and All Hazards Preparedness Act needs lean update

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Roche to buy Carmot Therapeutics, developer of obesity drugs

Swim instructor mom warns parents not to buy blue swimsuits for kids

Leukemia patients are helped by Syndax's new type of therapy

entertainment

knowledge

Wikipedia

Peter Hotez and the public health issue of online harassment

Pandemic and All Hazards Preparedness Act needs lean update

Affirmative action in medical school literally saved lives

Why sickle cell disease is getting the first CRISPR treatment

Peter Hotez and the public health issue of online harassment

Spinal cord stimulation reduces pain in amputees, study finds

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Roche to buy Carmot Therapeutics, developer of obesity drugs

Drug repurposing or repositioning? The language matters

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Wikipedia

FDA approves world's first CRISPR

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Parents surprise family after baby discharged from NICU after 170 days

Patients' immediate access to test results puts radiologists in a bind

FDA needs staff influx to meet gene therapy needs, Marks says

Eisai exec who led development of Alzheimer’s drug to retire

explore

hotspot

hotspot

explore